Pfizer’s shares sank significantly on Tuesday as global markets rose steadily. Analysts downgraded the firm over weak drug prospects. Some investors remain concerned the pipeline appears limited and leadership is still shaky.
But Pfizer earned a key approval: the first CDK4/6 maintenance therapy for advanced HER2-positive breast cancer. Still, the stock losses overshadowed the good news. Offices in Midtown Manhattan evacuated after beams buckled, raising collapse concerns.